Innovacell is a late-stage biotech developing cell therapy treatments for incontinence (fecal & urinary). We are headquartered in Tokyo (Japan) and have a 100% subsidiary in Innsbruck (Austria). Our aim is to obtain approval for our lead program, ICEF15 (an autologous cell therapy treatment for urge fecal incontinence), across Japan, Europe and the US after a successful completion of our ongoing phase 3 multi-regional clinical trial. We have been operating a proprietary manufacturing facility in Innsbruck for more than 15 years and this has allowed the company to keep the per-dose COGS low despite the fact ICEF15 is an autologous cell therapy.